<DOC>
	<DOCNO>NCT00394147</DOCNO>
	<brief_summary>The purpose study look well combination two chemotherapy drug , pemetrexed ( Alimta ) gemcitabine ( Gemzar ) work treat cancer .</brief_summary>
	<brief_title>Pemetrexed Gemcitabine Patients With Advanced Head Neck Cancer</brief_title>
	<detailed_description>This research study do yet able find best treatment recurrent advance head neck cancer ( SCCHN ) . Pemetrexed gemcitabine help fight SCCHN give . This study different others test two drug together , try patient SCCHN . We see well drug work help control shrink cancer . We also want find effect ( good bad ) gemcitabine pemetrexed head neck cancer . We know drug help . Your cancer might get good might get bad . It might effect condition . We use learn research study help people cancer .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Diagnosis squamous cell cancer head neck unresectable metastatic . Must measurable disease RECIST . Karnofsky performance status great equal 60 % Up one prior systemic chemotherapy , immunotherapy allow advanced metastatic setting . This include prior chemotherapy , immunotherapy use radiotherapy ( ie concurrent radiation therapy induction regimen pror definitive radiation therapy ) . At least 4 week prior radiation chemotherapy , must recover acute effect treatment . Adequate organ marrow function Negative pregnancy test . Agree use birth control 3 month last dose study drug . At least 18 year age . Sign inform consent HIPAA consent . Must able take absorb enteral medication . Serious concomitant systemic disorder would compromise safety ability complete study . Prior treatment gemcitabine pemetrexed within previous year , unless use concurrently radiation therapy . Pregnancy breastfeed . Symptomatic uncontrolled brain mets . If treat , must steroids least 2 week . Inability unwilling take folic acid , vitamin B12 , dexamethasone . Treatment within last 30 day drug receive regulatory approval indication . Inability interrupt NSAID salicylate long halflife ( piroxicam nabumetone ) 5 day period . Presence clinically relevant third space fluid control drainage procedure prior study entry . Active , concurrent , invasive malignancy require ongoing treatment . Corticosteroids impermissible unless adrenal failure , septic shock temporize measure symptomatic pain , breathing , rash .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>advanced</keyword>
	<keyword>head</keyword>
	<keyword>neck</keyword>
	<keyword>cancer</keyword>
</DOC>